Thomas Brevig, MD, PharmD

Assessing Experiences, Attitudes, and Perceptions Associated With Treatment-Resistant Schizophrenia: Caregiver Focus Groups

Background: Treatment-resistant schizophrenia (TRS), defined as schizophrenia not responding to two trials of antipsychotics (APs) of adequate dose and duration, affects about one-third o...

Dana DiBenedetti , PhD;

Dawn Velligan , PhD;

Steven Kymes , PhD;

Anne-Marie Kelnaes , MA;

Thomas Brevig , MD, PharmD;

03/01/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8

November 8 ⁠–⁠ November 10

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Thomas Brevig, MD, PharmD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products